XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Investments in Non-Marketable Securities - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2023
Jul. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jul. 31, 2021
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Nov. 30, 2023
Sep. 30, 2022
Mar. 31, 2022
Nov. 30, 2020
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Available-for-sale non-marketable interest-bearing debt securities           $ 0   $ 0 $ 0         $ 1,000
Non-marketable debt security at carrying value         $ 1,300                  
Interest income from amortization of discount                   $ 300        
Investments in non-marketable securities               1,191 5,300 7,630        
Investment in non-marketable equity securities ($0 and $13,921 with a related party)           9,700   9,700 20,510          
Revenues               70,143 138,590 104,754        
Impairment of investment in non-marketable securities               12,215 0 0        
Equity securities without readily determinable fair value, upward price adjustment, annual amount               200            
Equity securities without readily determinable fair value, upward (downward) price adjustment, annual amount               0 0          
Research and development revenue                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Revenues               27,237 21,914 34,097        
seqWell | Research and development revenue                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Revenues               $ 200            
Common Stock | seqWell                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Stock issued during period, shares, issued for services (in shares)               205,279            
seqWell                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Equity securities without readily determinable fair value (in shares)                         1,000,000  
Investment in non-marketable equity securities ($0 and $13,921 with a related party)           2,625   $ 2,625 5,000       $ 5,000  
Impairment of investment in non-marketable securities             $ 3,000              
Arzeda                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Investment in non-marketable equity securities ($0 and $13,921 with a related party)           82   82 1,289          
Impairment of investment in non-marketable securities           1,200                
Related Party                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Investments in non-marketable securities               0 0 7,630        
Investment in non-marketable equity securities ($0 and $13,921 with a related party)           $ 0   0 13,921          
Related Party | Research and development revenue                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Revenues               0 $ 1,245 $ 1,955        
MAI                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Impairment of investment in non-marketable securities               $ 8,000            
Series B-2 Preferred Stock                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Non-marketable debt security (in shares)         207,070                  
Series B Preferred Stock | MAI | Related Party                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Milestone payments received (in shares)   1,587,049 1,587,049                      
Series B Preferred Stock | Arzeda                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Equity securities without readily determinable fair value (in shares)                     207,070      
Series B Preferred Stock | MAI                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Investment owned, balance (in shares) 985,545                     9,198,423    
Investments in non-marketable securities $ 800     $ 7,000                    
Common Stock | seqWell                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Equity securities without readily determinable fair value (in shares)           205,279   205,279            
Common Stock | Arzeda                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Convertible preferred stock, shares issued upon conversion (in shares)                     41,414      
Series A and B Preferred Stock | MAI | Related Party                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Noncash or part noncash acquisition, noncash financial or equity instrument consideration, shares issued (in shares)               19,277,914            
Series C-1 Preferred Stock | seqWell                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Equity securities without readily determinable fair value (in shares)             88,256              
Common Stock Warrants | seqWell                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Equity securities without readily determinable fair value (in shares)           44,128 44,128 44,128            
Investment in non-marketable equity securities ($0 and $13,921 with a related party)             $ 400              
Series C And C-1 Preferred Stock | seqWell                            
Equity Securities without Readily Determinable Fair Value [Line Items]                            
Equity securities without readily determinable fair value (in shares)           1,088,256   1,088,256